Genzyme, Icahn Call Off Proxy Fight With Compromise Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
In exchange for withdrawing its proxy slate and agreeing to back Genzyme's nominees, Icahn Partners get two seats on biotech's board.
You may also be interested in...
With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles
Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant
With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles
Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant
Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn
Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.